NCT07917832
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
StatusNot Yet Recruiting
PhasePhase 2
SponsorM.D. Anderson Cancer Center
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and adverse events (AEs)
Timeframe: Through study completion; an average of 1 year.
Arms and interventions
Group AExperimental
Patients with CR after Cycle 3
Group BExperimental
Patients with less than CR after Cycle 3
Drugs: golcadomide, Obinutuzumab, Polatuzumab, Glofitamab
Sites
1 site in 1 country
- UT MD Anderson Cancer CenterHouston, Texas, United States